1 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| NAM Biotech Fund II, LLC - Series IIFiled to raise in 2017, with no closing reported yet. | 2017 | $40M | $0 | 0 |
| NAM Biotech Fund II, LLC - Series VFiled to raise in 2017, with no closing reported yet. | 2017 | $40M | $0 | 0 |
| NAM Biotech Fund II, LLC - Series VIFiled to raise in 2017, with no closing reported yet. | 2017 | $40M | $0 | 0 |
| NAM Biotech Fund II, LLC (Series I)Filed to raise in 2017, with no closing reported yet. | 2017 | $50M |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
1 partner is named across this firm’s filings, 1 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David Levine | Quiet | None listed | 3 | 0 |
Classified sectors of NAM Biotech’s own portfolio companies, based on 3 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of NAM Biotech’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
No other firm shares a filed board seat with NAM Biotech yet. That is a gap in what we have read, not a claim that NAM Biotech invests alone.
A shared board seat: a company where filings name a NAM Biotech partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.
| $0 |
| 0 |
| NAM Biotech Fund II, LLC (Series III)Filed to raise in 2017, with no closing reported yet. | 2017 | $40M | $0 | 0 |
| NAM Biotech Fund II, LLC (Series IV)Filed to raise in 2017, with no closing reported yet. | 2017 | $40M | $0 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
